Abstract: Poster Presentations |


C. S. McSwain, MHSc; Ray Benza, MD; Shelley Shapiro, MD, PhD; Nicholas Hill, MD; Robert Schilz, DO, PhD; C. G. Elliott, MD; Diane L. Zwicke, MD; Ronald Oudiz, MD; James P. Staszewski, PhD; Carl P. Arneson, MStat; David Zaccardelli, PharmD; Vallerie McLaughlin, MD*
Author and Funding Information

University of Michigan Medical Center, Ann Arbor, MI


Chest. 2007;132(4_MeetingAbstracts):634b. doi:10.1378/chest.132.4_MeetingAbstracts.634b
Text Size: A A A
Published online


PURPOSE: This study assessed the relationship between dose and plasma concentration following administration of treprostinil sodium (Remodulin®) infusion therapy in pulmonary arterial hypertension (PAH) patients.

METHODS: This was a multi-center, open-label, multiple cohort, steady-state, pharmacokinetic study in subjects with PAH receiving treprostinil by continuous intravenous or subcutaneous infusion at doses between 10-125 ng/kg/min. A blood sample was obtained from each patient at steady-state and analyzed via a validated liquid chromatography tandem mass spectrometry (LC/MS/MS) method.

RESULTS: Forty-nine PAH subjects receiving treprostinil, 37 (76%) intravenously and 12 (24%) subcutaneously, were enrolled. Treprostinil doses ranged from 12.1-125 ng/kg/min; treprostinil plasma concentrations ranged from 14.9-18,248 pg/mL. Linear regression analysis revealed a correlation between treprostinil dose and treprostinil plasma concentration with an R2 value of 0.561 (n=49). Using a power model to assess dose proportionality, the estimated non-proportionality parameter was 0.641 (95% CI: 0.083-1.199), reflecting consistency with dose proportionality. Subset linear regression analysis, which excluded two subjects with anomalous treprostinil plasma concentrations, increased the R2 value to 0.796 (n=47). Using a power model to assess dose proportionality of this subset, the estimated non-proportionality parameter was 0.941 (95% CI: 0.809-1.073). A post-hoc review of the data, using a general linear model for analysis, revealed the relationship between dose and concentration was not related to route of drug administration [p=0.25 for n=49 (with outliers); p=0.83 for n=47 (with outliers excluded)].

CONCLUSION: This study supports previous findings of linearity at lower doses up to 15 ng/kg/min and demonstrates linearity at treprostinil doses up to 125 ng/kg/min.

CLINICAL IMPLICATIONS: These results provide added assurance that, for the vast majority of patients, an increase in the infusion rate of treprostinil, whether via the subcutaneous or intravenous routes, yields a proportional increase in treprostinil plasma concentrations.

DISCLOSURE: Vallerie McLaughlin, No Product/Research Disclosure Information; Shareholder I, Christopher Shane McSwain, possess stock options to purchase shares of United Therapeutics’ stock; Employee I, Christopher Shane McSwain, am employed by United Therapeutics Corporation as an Associate Manager, Clinical Affairs.

Wednesday, October 24, 2007

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543